The peroxisome proliferator-activated receptor γ （PPARγ） is the nuclear receptor responsible for transducing the therapeutic activity of the thiazolidinediones （TZDs）. TZDs are a group of structurally related synthetic PPARγ agonists with antidiabetic actions in vivo. Rosiglitazone is a prototypical TZD and has served as a reference compound for this class. There are many PPARγ agonists， including 15-deoxy-Δ12，14-prostaglandin J2 and azelaoyl PAF， which are naturally derived. However， only a few antagonists have been reported. GW 9662 blocks the PPARγ-induced differentiation of monocytes to osteoclasts by >90% at a dose of 0.1 uM. It is therefore a much more potent antagonist than BADGE， which is another reported PPARγ antagonist.
产品描述
An internal standard for the quantification of GW 9662 by GC- or LC-MS
